Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, will be speaking at University of Miami
The Chief Scientific Alliance Officer of IAG, Dr. Diana Dupont-Roettger, will be giving a virtual talk at the Clinical Brain Tumor Research meeting at University of Miami on 25 February 2021.
The title of the talk will be Advanced Imaging Approaches in Neuro-Oncology and Neurosurgery
Key discussions points include:
- Advanced imaging methods to show tumour reoccurrence and early treatment related changes
- The potential of Imaging Biomarkers: AI, Radiological Phenotyping, True Progression vs. Pseudo-Progression
- Global imaging strategies for clinical trials
- Virtual Reality: Fusion of imaging markers and digital pathology
About the University of Miami Brain Tumor Initiative
The Sylvester Comprehensive Cancer Center Brain Tumor Initiative (BTI) strives to close the gap between pioneering research and promising treatments. We do this by exploring how cancers develop and progress and the intricacies of cellular interactions within tumors. By evaluating a tumor’s genetic profile and how it responds to medication, our researchers identify changes at the molecular level. In this way, we develop customized treatment plans using the latest evidence-based protocols.
To prevent or control tumor growth, we study a variety of factors, including how inflammation, immunity and conditions like obesity affect tumors. Some of our neuro-oncologic trials focus on immune-modulated tumor therapy using vaccines, radiation therapy and surgical procedures.
About Dr Diana Dupont-Roettger
Diana is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers as well as their role for biotech and pharma. She is an expert in scientific imaging clinical trial design and advises biotech and pharma on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.
About IAG, Image Analysis Group
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. https://www.ia-grp.com